Every provider needs to know the potential revenue for establishing a new business line. The new Medicare Home Infusion benefit allows home infusion for thirty-five (35) drugs initially. The allowed drugs will be expanded in 2020 and 2021. MJS has prepared a white paper titled “Potential Medicare Payment Under the Temporary Home Infusion Rates” that describes the revenue potential for ten (10) of the currently approved drugs. Potential revenue by drug includes the infusion services, pharmacy, supplies and equipment as listed in the 2019 Home Health Final Rule and the Medicare DME, supplies, and drug database payment rates for 2019. This white paper is available free to interested providers with your email registration below.